Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342379 · ClinicalTrials.gov registry record · Phase 2
TH-302 in Combination With Bevacizumab for Glioblastoma
A Phase 2 study of Glioblastoma, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 2
- Study locations
NCT02342379 is a Phase 2 study of Glioblastoma that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 35 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02342379, a Phase 2 study of Glioblastoma, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 2
- Study locations
Study Summary
Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG TH-302
Study Locations (2)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Texas
- University of Texas Health Science Center San Antonio at the Cancer Therapy and Research Center - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342379
The ClinicalTrials.gov registry entry for NCT02342379 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (68% lower). The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02342379 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Texas.
Frequently Asked Questions
What is clinical trial NCT02342379 about?
NCT02342379 is a clinical study titled "TH-302 in Combination With Bevacizumab for Glioblastoma". Dual center, single arm, two-stage, non-blinded, prospective study of combination therapy bevacizumab at 10mg/kg and TH-302 at 670mg/m2 every 2 weeks (6 week cycle) until disease progression.
What is the current status of trial NCT02342379?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2015-05. Estimated completion is 2019-12-04.
What conditions does trial NCT02342379 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT02342379?
The interventions under investigation include: Bevacizumab (DRUG), TH-302 (DRUG).
Who is sponsoring clinical trial NCT02342379?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02342379 being conducted?
This trial has 2 study locations across Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.